XNAS
TRAX
Market cap1.25bUSD
Oct 16, Last price
34.46USD
1D
-4.38%
1Q
-5.63%
IPO
85.27%
Name
First Tracks Biotherapeutics Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shs. 5Y
—
Rev. 5Y
%
Revenues
0
Net income
-166m
CFO
-143m
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory diseases. The company, founded in 2025, has its headquarters in San Diego, California, and operates as a subsidiary of AnaptysBio, Inc.
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
WILMINGTON, DE 19808
US
Headquarters
10770 Wateridge Circle, Suite 210
San Diego, CA 92121
US
San Diego, CA 92121
US
Valuation
Title in thousands, except ratios and share amounts | FY |
|---|---|
| 2025‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT |